# When Weight Comes Back After Bariatric Surgery: What a GLP-1 Adds

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/glp1-after-bariatric-surgery-weight-regain

> Pooling 19 studies of people who regained weight or never lost enough after surgery, adding a GLP-1 produced a mean further loss of 7.02 kg, at doses well below what is prescribed today.

## Key points

- 19 studies: mean further loss of 7.02 kg and 3.07 kg/m² of BMI after surgery.
- Pooled effect Cohen's d 0.470: moderate, not comparable to the operation itself.
- The studies used semaglutide at 1 mg weekly. That is the DIABETES dose; weight management is 2.4 mg.
- Nobody has run a withdrawal trial in post-surgical patients, so ask about stopping before starting.

Weight coming back after bariatric surgery is common, it is not a moral failure, and it now has a pharmacological answer with evidence behind it. Pooling 19 studies of people who had regained weight or never lost enough after surgery, adding a GLP-1 produced a mean further loss of **7.02 kg**.[1] A second review put the pooled effect at a Cohen’s d of 0.470, a moderate effect.[2] Almost every summary of this evidence leaves out the doses those studies used, and that changes how you should read the numbers.

## Why weight returns after surgery

Two distinct things get conflated. **Insufficient weight loss** means the operation never produced the expected result. **Weight regain** means it did, and then some of it came back. They have different causes, and the literature increasingly treats them separately, though both respond to the same intervention.

Neither is unusual. Surgery changes the anatomy and much of the hormonal signaling, but it does not switch off the biology that defends a body weight, and over years that biology reasserts itself in a substantial minority of people. Anyone who has been told this is a matter of willpower has been told something the surgical literature does not support. The same moralizing [follows people who lose weight with a GLP-1](https://glpwatchdog.org/research/judged-worse-than-not-losing-weight).

## What adding a GLP-1 achieved

*GLP-1 drugs added after metabolic bariatric surgery for regain or insufficient loss.*

| Analysis | Finding |
| --- | --- |
| 19 studies, systematic review and meta-analysis[1] | Mean difference −7.02 kg, and −3.07 kg/m² in BMI |
| Pooled systematic review[2] | Cohen’s d 0.470 (p ≤ 0.001) — a moderate effect |
| Safety[1] | Reported as safe in this population; the adverse effects were the class’s usual ones |

In plain terms, a Cohen’s d of 0.470 is a moderate effect: noticeably better than nothing, and nowhere near what the original operation did. The second review’s own framing is that these drugs “show promise and deserve additional research” as part of standard care after surgery, which is a fair reading of a moderate pooled effect.[2]

## The dose almost nobody mentions

In the included studies, the highest doses used were liraglutide 3 mg daily and semaglutide **1 mg once weekly**.[1]

> 1 mg weekly is the diabetes dose. The weight-management dose is 2.4 mg.

So this evidence was generated at less than half the semaglutide dose someone would now be prescribed for exactly this problem. That cuts two ways. The effect at current doses may be larger than 7 kg. But nobody has measured that, and the figure that circulates comes from a dose most of these patients are no longer given.

> **This is what a fast-moving field looks like.** Trials are run at the doses available when they start, and dosing moves on. That is no flaw in the research, but it does mean a pooled number like this one is better read as a floor than as an estimate of what today’s doses do.

## Two different failures, and only one has a randomized trial

**Regain** after a good initial loss and **never losing enough in the first place** are routinely discussed as one thing, but the evidence differs sharply between them.

For insufficient initial loss, there is now a proper trial. BARI-STEP randomized 70 adults who were at least a year past gastric bypass or sleeve gastrectomy and had lost less than 20% of their weight from surgery, to semaglutide 2.4 mg or placebo, double-blind, for 68 weeks. Everyone also received a lifestyle intervention with a 500-calorie daily deficit.[4]

*BARI-STEP at 68 weeks, intention-to-treat.[4]*

|   | Semaglutide 2.4 mg | Placebo |
| --- | --- | --- |
| Weight change | **−18.0%** (SD 9.2) | **+0.4%** (7.0) |
| Adjusted treatment difference | **−19.18 percentage points** (95% CI −23.4 to −14.8), P < 0.001 | — |

> **Look at the placebo column. It went up.** These participants received a structured lifestyle program with a 500-calorie deficit for 68 weeks, and on average gained 0.4%. These were people whose weight had already failed to respond to major surgery, so that is less surprising than it sounds. It is also why the treatment difference here, over 19 percentage points, is among the largest in this literature.

Adverse events matched the drug’s known profile, with no new concerns specific to operated anatomy. There were eight serious adverse events and one suspected unexpected serious adverse reaction (the published abstract does not describe it), and no treatment-related deaths.

## For regain specifically, the evidence is weaker

A 2026 cohort followed 34 people with recurrent weight gain after bariatric surgery or [an endoscopic procedure](https://glpwatchdog.org/research/endoscopic-sleeve-versus-surgical-sleeve) through 24 weeks of tirzepatide at 2.5 to 10 mg weekly. Mean total body weight loss was **18.1% ± 5.6%** (P < 0.0001).[3]

> **The sample behind that figure is 34 people with no control group.** An observational cohort of volunteers who sought treatment for regain is not comparable to a randomized population, and the doses used topped out at 10 mg rather than 15. The result is encouraging, but no one should plan around that rate.

## Questions worth asking first

- **Which problem is it?** Insufficient loss and regain are different, and a surgeon who distinguishes them is thinking about causes rather than reaching for the same answer twice.
- **Has anything anatomical been ruled out?** A dilated pouch or a widened outlet is a surgical finding with a surgical answer, and a drug will not fix it.
- **How will the gastrointestinal effects interact with the anatomy you now have?** Nausea and vomiting are the class’s commonest effects, and an altered stomach changes how they are experienced.
- **Who is managing this?** Bariatric follow-up and telehealth prescribing often do not talk to each other, and here they should.

Our [constipation guide](https://glpwatchdog.org/research/glp1-constipation-what-works) and [side-effect timeline](https://glpwatchdog.org/research/how-long-do-glp1-side-effects-last) cover the gastrointestinal side, and the [bariatric overlap cheat sheet](https://glpwatchdog.org/research/cheat-sheets/glp1-bariatric-surgery-overlap-cheat-sheet) covers which operation interacts with what.

None of this evidence addresses what happens when the drug stops. In people who never had surgery, the withdrawal trials are unambiguous that most of the weight returns (see [what happens when you stop](https://glpwatchdog.org/research/what-happens-when-you-stop-a-glp1)), and nobody has run that trial in post-surgical patients. If the drug is being added because weight came back once, ask about the plan for stopping it at the start.

## Frequently asked questions

### Do GLP-1 drugs work after bariatric surgery?

Yes, moderately. A meta-analysis of 19 studies in people with weight regain or insufficient loss after surgery found a mean further loss of 7.02 kg and 3.07 kg/m² of BMI, and a second review put the pooled effect at a Cohen's d of 0.470. That is a moderate effect: better than nothing, and nowhere near the original operation.

### Why did my weight come back after surgery?

Because surgery changes anatomy and hormonal signaling but does not switch off the biology that defends a body weight, and over years that reasserts itself in a substantial minority of people. The surgical literature treats this as an expected outcome in some patients, not a failure of willpower.

### Is the evidence based on current doses?

No, and this is rarely mentioned. The pooled studies used semaglutide at a maximum of 1 mg weekly (the diabetes dose) and liraglutide at 3 mg daily. The weight-management dose of semaglutide is 2.4 mg. The real effect at current doses may be larger, and nobody has measured it.

### Is it safe with a surgically altered stomach?

The systematic review reported it as safe in this population, with the class's usual adverse effects. Nausea and vomiting can feel different with altered anatomy, so raise it with the team that did the surgery, not only with whoever prescribes.

### What happens if I stop the drug?

Nobody has run that trial in post-surgical patients. In people who never had surgery, the withdrawal trials show most of the lost weight returns. If the drug is being added because weight came back once, ask about the plan for stopping before starting.

## References

1. Esparham A, Mehri A, Dalili A, et al. Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis. Obesity Reviews. 2024. PMID: 39134066. https://pubmed.ncbi.nlm.nih.gov/39134066/
2. Kellett J, Soliman SS, Podwojniak A, et al. The Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists for Insufficient Weight Loss or Regain After Metabolic/Bariatric Surgery: A Systematic Review and Meta-analysis. Obesity Surgery. 2025. PMID: 39910018. https://pubmed.ncbi.nlm.nih.gov/39910018/
3. Vinciguerra F, Di Stefano C, Guccione F, et al. Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety. Obesity Surgery. 2026. PMID: 42247124. https://pubmed.ncbi.nlm.nih.gov/42247124/
4. Stanley C, Mallik R, Hamid N, et al. Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial. Nature Medicine. 2026. PMID: 42174253. https://pubmed.ncbi.nlm.nih.gov/42174253/

---

Cite as: GLP Watchdog, Nora Bissett, "When Weight Comes Back After Bariatric Surgery: What a GLP-1 Adds", published 2026-08-19, updated 2026-10-30. https://glpwatchdog.org/research/glp1-after-bariatric-surgery-weight-regain

Canonical HTML page: https://glpwatchdog.org/research/glp1-after-bariatric-surgery-weight-regain

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
